BeOne MedicinesONC +2.38%80 Return-on-Tangible-Equity is 20.39% as of Mar. 2026. GuruFocus rates ONC with a GF Score™ of 80/100 and a GF Value™ of $367.20 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,196 Biotechnology companies, BeOne Medicines ranks better than 88.29% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. BeOne Medicines's annualized net income for the quarter that ended in Mar. 2026 was $909 Mil. BeOne Medicines's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $4,459 Mil. Therefore, BeOne Medicines's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 20.39%.
The historical rank and industry rank for BeOne Medicines's Return-on-Tangible-Equity or its related term are showing as below:
ONC'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -73.08 Med: -34.23 Max: 12.74
Current: 12.74
During the past 13 years, BeOne Medicines's highest Return-on-Tangible-Equity was 12.74%. The lowest was -73.08%. And the median was -34.23%.
ONC's Return-on-Tangible-Equity is ranked better than 88.29% of 1196
companies
in the Biotechnology industry
Industry Median: -42.19
vs ONC: 12.74
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
BeOne Medicines Return-on-Tangible-Equity Related Terms
BeOne Medicines Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ONC vs MRNA, RPRX, ROIV: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, BeOne Medicines's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 20.39% mean?
BeOne Medicines (ONC) has a Return-on-Tangible-Equity of 20.39% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #140 out of 1196 companies in the Biotechnology industry, placing it in the top 11.7%.
Is BeOne Medicines' Return-on-Tangible-Equity too high?
BeOne Medicines' current Return-on-Tangible-Equity is 20.39%. Based on the distribution chart, BeOne Medicines ranks #140 out of 1196 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BeOne Medicines has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Return-on-Tangible-Equity compare to MRNA and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #140 out of 1196 companies for Return-on-Tangible-Equity. This places BeOne Medicines in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Return-on-Tangible-Equity is 20.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $367.20, compared to a current price of $297.65 — trading 18.9% below its estimated fair value. The current Return-on-Tangible-Equity is 20.39%. BeOne Medicines' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Return-on-Tangible-Equity is 20.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $297.65 is trading 18.9% below its estimated GF Value™ of $367.20.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
Return-on-Tangible-Equity: 20.39%
GF Value™: $367.20 vs. price of $297.65 (18.9% below fair value)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
80GF Score
Get the complete analysis for ONC
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
